DDInter342 DDInter1819
Certolizumab pegol is a pegylated monoclonal antibody against the tumor necrosis factor-alpha (TNF-alpha). It is formed with a humanized Fab fragment of 50 kDa, from an IgG 1 isotype, fused to a 40 kDa polyethylene glycol moiety replacing the Fc antibody region. The absence of the Fc region was ideated to prevent complement fixation and antibody-mediated cytotoxicity as well as to markedly increase its half-life. Certolizumab does not require glycosylation for active function and hence, its production is significantly more affordable when compared to other existing TNF-alpha therapies as it can be done directly in bacterial hosts such as _E. coli_. It was developed and manufactured by UCB Pharma, first FDA approved in 2008 and updated for a new indication on March 28, 2019.
Tisagenlecleucel is a CD19-directed genetically modified autologous T cell immunotherapy, or a CAR-T cell therapy for B-cell acute lymphoblastic leukemia. It was granted approval by FDA in August 2017 under the market name Kymriah. Tisagenlecleucel is an immunocellular therapy that involves autologous T cells that are collected from each individual patient and genetically engineered to express a specific protein called a chimeric antigen receptor (CAR) that specifically target CD19 antigens. Modified T cells are infused back into the patient's body. These CD19-directed chimeric antigen receptors (CD19 CAR-T cells) direct the T cells to target and kill leukemia cells that express CD19 on the cell surface. In a multicenter clinical trial involving pediatric and young adult patients with relapsed or refractory B-cell precursor ALL, the overall remission rate within three months of treatment was 83 percent.
Certolizumab pegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Vitamin E
Certolizumab pegol {u} may cause a minor interaction that can limit clinical effects when taken with {v} Zinc gluconate
Certolizumab pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Stavudine
Certolizumab pegol {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Candida albicans
Certolizumab pegol {u} may lead to a major life threatening interaction when taken with {v} Abatacept
Certolizumab pegol {u} may lead to a major life threatening interaction when taken with {v} Tildrakizumab
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Vitamin E
Certolizumab pegol may cause a minor interaction that can limit clinical effects when taken with Zinc gluconate
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Stavudine
Certolizumab pegol may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans
Certolizumab pegol may lead to a major life threatening interaction when taken with Abatacept
Certolizumab pegol may lead to a major life threatening interaction when taken with Tildrakizumab